The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge.
- Author:
Daiana Cosmina TEMIAN
1
;
Laura Ancuta POP
;
Alexandra Iulia IRIMIE
;
Ioana BERINDAN-NEAGOE
Author Information
- Publication Type:Review
- Keywords: Breast neoplasms; DNA methylation; Histone code; Triple negative breast neoplasms; Untranslated RNA
- MeSH: Breast Neoplasms*; Breast*; Diagnosis; DNA Methylation; Epigenomics*; Female; Histone Code; Humans; Incidence; Methylation; Prognosis; RNA, Untranslated; Triple Negative Breast Neoplasms
- From:Journal of Breast Cancer 2018;21(3):233-243
- CountryRepublic of Korea
- Language:English
- Abstract: Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies–the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis–DNA methylation, histone modifications, and noncoding RNAs–advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.
